Bonus BioGroup initiated a preclinical study (&ldquo;the Study&rdquo;) of a unique drug product termed MesenCure, specially developed by the Company for the treatment of acute and life-threatening respiratory distress in coronavirus (COVID-19) and pneumonia patients.

Bonus BioGroup

Tel Aviv-Yafo

Bonus BioGroup startup from Tel Aviv-Yafo, Israel is ranked 1429 out of 2449 worldwide and 33 from the 60 startups in Israel. See more information and additional rankings on the StartupBlink Global Ecosystem Map